Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2022

View Archived Issues

FVIII-QQ gene transfer therapy shows advantage for treating hemophilia A

Novel genetic polymorphism associated with macroangiopathy risk

UCB SA patents DRD1 PAMs

Merck & Co. discloses new DNA polymerase inhibitors

Pfizer synthesizes IL-2 production inhibitors

Janssen Pharmaceutica identifies new Mcl-1 inhibitors

GLS1 inhibitor with antitumor activity in HCT116 xenograft model

Heptares Therapeutics divulges new histamine H4 receptor antagonists

Inflammation, coagulation and endothelial activation markers linked to HIV-associated TTP

A new series of broad-spectrum bacterial type II topoisomerase inhibitors: synthesis and evaluation

New salicylic acid derivatives act as double GO/LACH inhibitors to decrease oxalate production

SNP rs11549465 in HIF1A gene predicts glucocorticoid sensitivity in patients with ITP

FDA awards orphan drug designation to AVR-RD-05 for Hunter's syndrome

CytomX restructures and outlines plans for preclinical pipeline

KDM4B enzyme inhibitor tested for aggressive rhabdomyosarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...